Dr. Rahmo Showcases SMSbiotech’s Breakthrough Cell Therapy at Biotech Global Summit.
SMSbiotech is proud to announce that President and Chief Scientific Officer, Dr. Abdulkader Rahmo, presented our pioneering research at the Annual Global Summit on Public Health and Healthcare Systems (AGSPHHCS 2025). The conference took place in Bern, Switzerland, with Dr. Rahmo delivering his presentation virtually on September 19, 2025.
His talk, titled “Small Mobile Stem (SMS) Cells Potential Contribution to Treatments of Chronic Diseases,” highlighted how SMSbiotech’s proprietary SMS cell platform addresses major limitations of conventional cell therapy and holds the potential to transform regenerative medicine.
Key takeaways included:
- Industrial-Scale Production – SMS cells can be expanded extensively (over 27 passages) while maintaining potency and functionality.
- Targeted Action – SMS cells exhibit a high binding affinity for repair-related target cells, supporting more precise and consistent clinical outcomes.
- A Paradigm Shift – These breakthroughs pave the way for scalable, stable, and potent “off-the-shelf” (allogeneic) therapies designed for broad clinical application.
-
This platform is currently being evaluated in a Phase 1 clinical trial for Chronic Obstructive Pulmonary Disease (COPD)—a debilitating condition with no known cure.
We are honored to share this milestone with the global health community and remain deeply grateful for your continued support.
